Share repurchase programme


Novo Nordisk A/S - Share repurchase programme Bagsværd, Denmark, 13 October 2014 - On 7 August 2014, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15.0 billion to be executed during a 12-month period beginning 30 January

2014.
Under the programme initiated 7 August 2014, Novo Nordisk will repurchase B shares for an amount up to DKK 3.5 billion in the period from 7 August 2014 to 28 October 2014.
Since the announcement as of 6 October 2014, the following transactions have been made under the programme:

Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 9,330,000 2,460,015,309

6 October 2014 220,000 279.56 61,503,904

7 October 2014 210,000 273.54 57,443,631

8 October 2014 235,000 266.50 62,626,654

9 October 2014 235,000 266.14 62,541,984

10 October 2014 230,000 259.90 59,777,621


Accumulated under the programme 10,460,000 2,763,909,103

With the transactions stated above, Novo Nordisk owns a total of 45,041,289 B shares of
DKK 0.20, corresponding to 1.7% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,650,000,000 including treasury shares.

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 63 / 2014

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15.0 billion during a 12-month period beginning 30 January 2014. As of 10 October 2014, Novo Nordisk has repurchased a total of 42,197,995 B shares equal to a transaction value of DKK
10,468,427,602.

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately

40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's

B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock

Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge

+45 4442 3450

amhg@novonordisk.com

Investors:

Kasper Roseeuw Poulsen

+45 3079 4303

krop@novonordisk.com

Jannick Lindegaard Denholt

+45 3079 8519

jlis@novonordisk.com

Daniel Bohsen

+45 3079 6376

dabo@novonordisk.com

Frank Daniel Mersebach (US)

+1 609 235 8567

fdni@novonordisk.com

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

Company announcement No 63 / 2014

distributed by